Risks and Benefits of Liver Biopsy in Focal Liver Disease by Streba, Letiția Adela Maria et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Risks and Benefits of Liver Biopsy in Focal Liver Disease
Letiția Adela Maria Streba,
Eugen Florin Georgescu and Costin Teodor Streba
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52620
1. Introduction
Even with the recent evolution of imaging techniques, and with the ever-increasing role of
serum markers, direct analysis of tissue samples maintains its role in modern medicine. This
is especially true for the diagnosis and assessment of the prognosis and evolution of a series
of viral, tumoral and inflammatory liver diseases. Thus, liver biopsy and histological assess‐
ment of the liver parenchyma can still be called by many the “gold standard” in diagnosis
and staging of associated disease. However, liver biopsy in itself implies a series of risks and
inherent discomfort for the patient. With the increasing availability of other non-invasive
methods routinely used in diagnosis and staging of liver-related diseases, many debate the
necessity and ethical implications of tissue sampling.
In the following pages, we will try and synthetize the historical evolution of liver biopsy,
describe the techniques used over the years and present its current recommendations and
their alternatives,  with focus on the so-called “virtual liver biopsy” techniques currently
employed.
2. Historical landmarks and recent developments in liver biopsy
The first written documented report of a successful liver biopsy was made by Paul Ehr‐
lich in the book “On diabetes” published in 1884. He published an account of the proce‐
dure  performed in  1880  in  Berlin,  along  with  graphical  illustrations  of  the  instruments
and the liver samples collected. This came detailed account was based on previous theo‐
retical  advantages of  this  technique discussed by the French physician AGM Vernois in
1844, who in turn based his assumption on successful procedures performed for punctur‐
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ing purulent echinococcus, as early as 1825 (Récamier) and 1833 (Stanley). Cytology was
reported as a diagnosis method for liver disease by L. Lucatello (in Rome) in 1895, while
F. Schupfer performed liver and spleen biopsies with a thicker needle twelve years later,
in  1907.  This  new approach provided cylindrical-shaped tissue samples  which could be
histologically prepared and analyzed [1].
Other scarce accounts of successful procedures followed in the next couple of decades (Oli‐
vet, 1926; Huard 1935; Silverman, 1938; Baron, 1939; Kofler, 1940; Dible, 1943), using differ‐
ent aspiration techniques performed with different modified biopsy needles [1].
A new stage in modern liver biopsy techniques was reached when, in 1957 and repeated in
the following year, Menghini performed and reported on the first “one-second needle biop‐
sy” performed with a special small caliber needle with no trocar and a sharp bevel. This was
the first time needle liver biopsy was introduced worldwide as a praised diagnostic techni‐
que capable of providing enough histological material for an accurate interpretation of the
pathological changes present in the parenchyma [1].
Following this radical advancement, liver biopsy became more spread and the technique
evolved once modern imagistic  methods allowed for  better  and safer  puncturing of  the
liver parenchyma. Thus, the technique entered the image-guided age of investigation per‐
formed  under  computed  tomography  (CT)  or  ultrasound  (US)  real-time  screening.  Re‐
ports  from  Denmark,  China,  the  United  Kingdom,  France  or  the  United  States  of
America populated the 1960–1980 literature,  once the technique became widespread and
fully  acknowledged by the academic community.  Its  utility  in  diagnosing liver  diseases
and later  on  in  staging  hepatitis  or  malignancies  was  undisputed  for  entire  decades  of
the 20th century [1].
Recent advancements, based on the advent of new imagistic high-accuracy techniques based
on both US and CT/RM approaches, highly diminished the role played by this invasive in‐
vestigation. The term “virtual biopsy” became more and more present in recent literature,
once both doctors and patients alike became more confident and were introduced to these
high-yield methods, such as Transient or Acoustic Radiation Force Elastography. Moreover,
advanced serum markers (such as, for example, the Fibrotest-Actitest battery of tests) allow
for an accurate non-invasive staging in hepatitis. The introduction of arterial uptake con‐
trast-enhanced US and CT/RM techniques substantially decreased the role of biopsy in diag‐
nosing liver biopsy [2–4].
However, histology remains one of the most accurate methods for evaluating liver paren‐
chymal changes, and is always used in malignancies when the diagnosis is uncertain or
when other non-invasive methods fail to provide an accurate staging for hepatitis. Along
with these non-invasive techniques came a revolution in in-situ biopsy methods. Such is
probe-based confocal laser endoscopy (pCLE), which uses miniaturized probes connected to
a laser source through fiber optics, small enough to fit inside a biopsy needle, thus provid‐
ing rapid live assessment of liver architecture [5].
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3. Modern liver biopsy techniques and sampling adequacy
3.1. Percutaneous biopsy
All modern percutaneous liver biopsy techniques have rapidity as a common denominator.
Either cutting or suction needles can be used for transthoracic or subcostal biopsy, either af‐
ter palpation or imaging assessment of the puncturing zone, or, preferably, under continu‐
ous image guidance. The transthoracic approach is the preferred method used, under real-
time US or (more rarely) CT guidance and after a thorough imaging investigation of the
liver and puncture route. All percutaneous methods imply two phases, one extra-hepatic
corresponding to the needle puncturing the skin and reaching the needle, and a hepatic
stage in which the needle passes the liver capsule, collects the parenchyma material, and is
swiftly extracted. It is considered a relatively safe procedure, complication rates varying be‐
tween studies, from 0.75% up to 13.6% [6].
Trucut needles and their modified versions driven by spring-loaded biopsy guns are in‐
creasingly used and are the instruments of choice in many centers worldwide, especially in
Europe [7]. Needle diameters vary between 1.20 mm to 1.60 mm, smaller calibers being used
when a high risk of complications is suspected.
Suction needles are less expensive and their operation allows for rapid intra-hepatic han‐
dling, thus being easier to use and possibly imply less bleeding-related complications. The
most widespread types are the Menghini, Jamshidi and Klatskin needles, which remained
virtually unchanged since their introduction in the second half of the last century. The maxi‐
mum required time for a complete syringe suction of the cytological material and the con‐
secutive needle retraction is 0.5 seconds. The intrahepatic phase is reduced to as low as 0.1
seconds when the needle is operated by an expert practitioner [8].
Image guidance has become mandatory in centers where the gastroenterologist can perform
his or her own US exam. Real-time surveillance of the procedure greatly decreases the risk
of complications (such as bleeding) and minimizes post-procedural complaints such as pain
or hypotension. Hepatologists in the United States usually prefer to have a radiologist per‐
forming the procedure under CT or US guidance [8].
3.2. Transjugular (transvenous) biopsy
The transjugular route is preferred when the risk for complications is high and therefore a
percutaneous approach is not considered safe enough for the patient. Patients with clinical
ascites, known hemostatic defect, cirrhotic liver with clinical signs of organ deficiency
(smaller size and increased palpatory stiffness) or morbid obesity are usually prime candi‐
dates for this approach. Another situation when the transvenous approach is preferred is
when additional pressure measurements in the hepatic vein are required [8].
The resources needed for this procedure are higher than percutaneous approaches; howev‐
er, complication rates are lower (2.5% up to 6.5%) according to some authors [9], with mor‐
tality rates of approximately 0.09% in high-risk patient groups [10]. The expertise of the
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performing physician also plays a crucial role in the success rate of this procedure, and
should be considered along with the higher resource costs when choosing this access route
for a lower-risk patient [1].
Another very important aspect is the lower quality of the tissue specimens collected through
the transjugular approach. The tissue cylinders are thinner and more fragmented than those
obtained through percutaneous biopsy, and usually represent only 1-2 cm of the liver paren‐
chyma, containing fewer portal fields [11].
3.3. Surgical or laparoscopic biopsy: Novel approaches for liver biopsy
This  approach is  preferred in  patients  with peritoneal  involvement  when an abdominal
cancer  is  present,  with associated ascites  or  peritoneal  disease with ascites  of  suspected
hepatic origin. Also, focal hepatic lesions can be targeted for biopsy through the laparo‐
scopic channel.
Biopsy can thus be performed with either normal needle systems, or by wedge resection.
However, the later approach may overestimate the level of fibrosis, as the resection is per‐
formed too close to the fibrotic capsule that envelops the liver. The procedure is always con‐
ducted under general anesthesia and requires controlled pneumoperitoneum by infusion of
nitrous oxide, always performed by trained physicians, allowing for a good control of bleed‐
ing and a minimum set of complications due to the large working area created. In direct
comparison with percutaneous biopsy, the laparoscopic approach provides a higher level of
accuracy as it allows the evaluation of the surrounding peritoneum [12]. The main complica‐
tions are related to the general anesthesia used for the procedure, the local abdominal and
intra-peritoneal traumas associated, as well as the risk of bleeding, which is also present in
the other types of biopsy.
Advancements to surgical techniques led to the development of the natural orifice translu‐
minal endoscopic surgery (NOTES), a new surgically-derived endoscopic technique that
uses a transgastric or transanal route to facilitate the access to the abdominal cavity. One re‐
cent study presented a liver biopsy performed through a transgastric flexible endoscopic de‐
vice which permitted the inspection of the liver and surrounding intraperitoneal space. The
technique can be applied to morbidly obese patients or to patients at high risk of complica‐
tions [13]. This approach remains however limited at the present time to a few highly select‐
ed patients, and is performed only by trained surgeons and gastroenterologists, at moderate
to high costs and in selected centers.
Recent studies also focused on evaluating the liver capsule in cirrhotic patients through
pCLE inserted through a laparoscopic channel, this being a promising field in the advance‐
ment of minimally invasive biopsy techniques [14]. Another study describes the use of pCLE
in a routine minilaparoscopy setting, performed under conscious sedation. The authors
could describe subsurface serial images in real time, allowing for an in vivo analysis of the
liver parenchyma [5]. This approach may lead the way to targeted biopsy through live as‐
sessment of the liver parenchyma, as well as immediate morphological and dynamic evalua‐
tion of intrahepatic structures.
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3.4. Adequacy of liver biopsy samples
Analysis of the biopsy material under ultraviolet fluorescent light may be required in order
to identify porphyria. Liver tissue obtained through biopsy is then quickly transferred into a
buffer solution, usually 4% or 10% neutral formalin, to avoid the alterations it may sustain
due to hepatic enzymes autolysis. It can then be subjected to various preparation techniques,
in accordance to what diagnostic tests will follow with that specific sample (frozen section,
RNA detection etc.) [1].
An adequate biopsy fragment is between 1 and 4 cm long, weighting between 10 to 50 mg,
with a minimal diameter of 1 mm. Fragmented samples from Menghini needles are accepta‐
ble, as their added size is somewhere in the vicinity of 2 cm (usually range from 1 to 2.5 cm
in length). In order to properly represent the parenchymal architecture, at least 10–11 portal
tracts should be completely present, six being a minimally acceptable number. Specimens of
inadequate lengths usually lead to understaging of fibrosis and underestimate the grade of
inflammation. Cirrhotic parenchyma usually comes fragmented through biopsy, thus lead‐
ing to approximately 20% sampling errors [15, 16].
As it is appreciated that a liver biopsy specimen represents 1/50 000 of the total organ mass,
discussions regarding how representative it can be for diffuse lesions always existed in the
literature [8, 17]. It is however appreciated that most diffuse (steatosis or inflammation etc.)
or focal lesions (both malignant and benign), as well as structural lesions such as fibrosis can
be visualized with a fairly high degree of accuracy, if the minimum amount of liver paren‐
chyma and the required number of portal spaces are present. It was however demonstrated
that the size of the sample is directly correlated to an underestimation of inflammatory
changes [18], this paradigm being extended to fibrotic changes and has a direct effect on the
subsequent grading and staging [1, 19, 20].
Another issue highly debated in literature is the inter-observer variability; even with the
wide usage of quantification scores for both inflammation and fibrosis such as the Knodell
[21] scoring system and the revised Ishak version [22] or the METAVIR score [23]. All inter‐
pretations are subjected to the experience and training of the pathologist, which is an inde‐
pendent variable in itself, separated from the inherent sampling and procedural errors. A
second opinion is always recommended, and two pathologists are usually present in most
large referral centers. Collaboration between the pathologist and the clinician performing
the liver biopsy is also preferred, as some studies indicated [24–26].
The most important quantification parameters refer to its geometry and relationship be‐
tween the principal compartments – portal tracts and the elements of the arterial vascular
system; the configuration adopted by hepatocyte plates; the sinusoids and the perisinusoi‐
dal compartment; the amount of connective tissue, fat and the number of ducts present, as
well as other normal cellular infiltrates of lymphoid origin [8]. Regenerative nodular hyper‐
plasia or macronodular cirrhosis can be sometimes classified as normal parenchyma, and
the inherent variations of normal inflammatory cellular infiltrate can be misleading for an
inexperienced pathologist when observing low grade inflammatory lesions [8, 27].
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4. Risks, complications and post-procedural complaints of liver biopsies
The main risks for a patient subjected to liver biopsy were already briefly discussed in the
previous paragraphs. Their frequency and predisposition in certain patient groups are de‐
terminant factors for choosing one biopsy technique in favor of another. The risk of bleeding
cannot be excluded with any instrument, and liver biopsy is not recommended in most cases
of suspected primary liver cancers because of a needle track seeding of tumor cells. These
however do not exclude liver biopsy as a last resort diagnostic tool, when imagistic or serum
tests proved constantly inconclusive or do not converge to an outcome.
The most commonly occurring complication of percutaneous liver biopsy is pain, present in
up to 84% of procedures and ranging from mild discomfort to severe pain [28]. It is usually
located in the right upper quadrant and it is referred to the right shoulder, with various in‐
tensities and time of installment. Moderate to severe pain is present in fewer than 5% of all
patients, and may be the sign of a more severe complication such as bleeding or the punc‐
turing of the gallbladder [16, 29]. Mechanisms that lead to pain after the biopsy maneuver
are not fully understood, however it is likely to be caused by bile or blood extravasation
with subsequent capsule swelling (the only liver component with sensitive nervous termina‐
tions) [30]. Another cause of upper abdominal pain is the traction of the falciform ligament
after the puncture. Cervical pain, as well as pain in the right shoulder, may also be caused
by the irritation of the phrenic nerve. Subcapsular hematoma may lead to respiratory pain
and irritation of the pleura or peritoneum may lead to vagal stimulation and consecutive va‐
gal shock, manifested through bradycardia, severe hypotension, weak pulse and intense
pain in the upper abdomen [1]. In some cases of extreme pain, hospitalization and further
imaging tests are required to determine the correct course of action for these patients.
However, the most important complication of liver biopsy is bleeding. The most severe
bleedings occur intraperitoneally, when they determine a drop in vital signs and can be vi‐
sualized through imaging [16, 31]. Urgent hospitalization and blood transfusion, even fol‐
lowed by surgery or radiological intervention may be required. Nevertheless, these cases are
scarce, with 1 in 2 500 up to 10 000 biopsies incidence, while less severe cases which do not
require blood transfusions or surgical maneuvers are more frequent, approximately 1 in 500
biopsies [16]. Serious bleeding-related complications usually occur within 2 hours of the
procedure, and over 90% of all bleedings become evident within 24 hours of the procedure.
Clinical symptoms are revelatory, as patients experience hypotension and shock. Age and
the underlying conditions also are predictive factors, as older patients and liver masses are
more frequently associated with post-puncture bleeding. A correlation between the needle
type and the risk for bleeding was also cited in literature, as cutting needle seem to pose an
increased risk compared to their suction counterparts [15]. Other factors are related to oper‐
ator experience, the diameter of the needles and their diameter [16].
A correlation between conventional coagulation tests and the risk of bleeding has not been
sufficiently demonstrated until now; therefore no certain recommendations in this regard
are currently in place [16]. The option to insert coagulation agents on the needle tract is con‐
sidered, especially in the US, with no definite data on its ability to prevent possible bleed‐
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ings. As already mentioned, the transvenous approach is preferred in certain categories of
patients as it is considered safer, even though several pooled analyses showed similar risks
with standard percutaneous methods [10,16].
The singular major complication of liver biopsy, caused in turn by consecutive severe bleed‐
ing is patient death. No consistent data regarding post-procedural mortality exists in the lit‐
erature, the most commonly quoted rate being less or equal to 1 in 10 000 biopsies [16], and
seems to be greater after biopsies of malignant liver masses compared to diffuse parenchy‐
mal disease [6].
Other complications of liver biopsies include the perforation of other viscous organs, bile
peritonitis (major complication which can result in death), infections (especially in post-
transplant patients due to immunosuppressive medication), hemobilia, pneumothorax (in‐
stantly recognized on radiographs, essentially to diagnose quickly due to high risk of death)
or hemothorax. Correct usage of imaging methods both when choosing the biopsy site and
for surveillance of the procedure minimizes many of these risks, especially those related to
puncturing adjacent structures [16]. The risk of needle track seeding when puncturing liver
malignancies exists in 1 to 3% of all cases [32], as will be detailed below.
5. Current recommendations regarding conditions that require liver
biopsy
The indications for liver biopsy were greatly reduced since the recent introduction of accu‐
rate non-invasive tests which can evaluate liver parenchyma with minimal or no patient
trauma. The concept of liver biopsy may evolve even further, if in vivo direct histological
methods such as pCLE will provide important additional data. It is most likely that the rec‐
ommendations for liver biopsy will suffer further changes in following years. A series of
these advancements will be discussed separately within this chapter. Below, we will de‐
scribe some of the main indications for liver biopsy, either for diagnostic purposes or for
evaluating and staging liver disease.
5.1. Grading and staging of chronic viral hepatitis
The recent outburst of viral hepatitis cases (especially as a result of the increasing number of
newly diagnosed virus C infections) represents a major health burden worldwide. With al‐
most four million people being infected in the United States alone, and between 130 and 170
million worldwide, chronic hepatitis C virus (HCV) infections and more than double those
figures for hepatitis B virus (HBV) infections, this ensemble of viral diseases currently repre‐
sent the main cause of liver-related morbidity [33, 34].
Nowadays, the role of liver histology in the positive diagnosis of chronic viral hepatitis has
greatly diminished. However, it still plays a central role when assessing both activity and
progression of the disease [8, 35]. Sampling issues arise when evaluating liver parenchyma
affected by chronic hepatitis, as the quality of the obtained specimens can greatly influence
Risks and Benefits of Liver Biopsy in Focal Liver Disease
http://dx.doi.org/10.5772/52620
91
the semi-quantitative scores developed in the last four decades to quantify disease progres‐
sion. There are a number of changes present within the liver and their heterogeneity makes
the “10-complete portal spaces” paradigm essential when evaluating disease severity. All
scoring systems are bound to yield significantly different results, primarily because of sam‐
ple variability, but also as a result of the different levels of expertise from the pathologist
involved in their evaluation. All modifications of the liver parenchyma – inflammation, ne‐
crosis or fibrosis – exhibit particularities and can be subjectively interpreted even in a scor‐
ing system [8].
The first approach to liver biopsy scoring for chronic hepatitis dates from the early 1980s
when the histological activity index (HAI) was introduced by Knodell and Ishak [21]. This
model did not clearly delimited between disease grades (that is, the importance of any in‐
flammatory activity present) and stage, which refers to the degree of fibrosis and parenchy‐
mal remodeling. The later modification performed by Ishak resolves most of these issues
and is currently used worldwide, partially replacing or at least complementing the earlier
alternative Knodell classification. The preferred approach is a parallel evaluation using sev‐
eral scoring methods, such as the modified HAI, the Scheuer or the Ludwig systems and the
Knodell classification, or the METAVIR algorithm devised in France [23].
5.2. Abnormal hepatic biochemical tests, alcoholic and non-alcoholic liver disease
Chronically elevated hepatic biochemical parameters are a common concern for many pa‐
tients during routine screenings or general consults. Gastroenterologists facing abnormal as‐
partate aminotransferase/alanine aminotransferase, gamma-glutamyltransferase or alkaline
phosphatase levels have to conduct a thorough anamnesis to determine the underlying con‐
dition. Many such patients either acknowledge high alcohol consumption or are diagnosed
with non-alcoholic liver disease (NAFLD) associated with their lifestyle, while few remain
undiagnosed until they begin to display signs of liver cirrhosis (cryptogenic cirrhosis or cir‐
rhosis of unknown etiology). The latter two classes are usually diagnosed through liver bi‐
opsy, as no other condition can be found from either their background or non-invasive
investigations and blood tests [8, 16].
The most common aspect revealed by liver biopsy in these patients is macrovesicularsteato‐
sis, intracellular lipid accumulation exceeding 5% of the total cellular population. This mac‐
rosteatosis is generally coined as fatty liver disease (FLD) and can either be identified as
either alcoholic liver disease (ALD), when regular alcohol consumption above established
thresholds is established, or NAFLD when obesity, type 2 diabetes mellitus and/or hyperli‐
pidemia are associated. Steatohepatitis, either of alcoholic origin (alcoholic steatohepatitis –
ASH) or metabolic (non-alcoholic steatohepatitis – NASH) share histological similarities.
NASH is recognized as a form of NAFLD with ballooning hepatocytes and necroinflamma‐
tory changes, as well as fibrosis and parenchymal remodeling. The NAFLD activity score
(NAS) was developed in an attempt to objectively quantify the extension of this disease.
This score sums the three pathologic features – steatosis, lobular inflammation and hepato‐
cellular ballooning on a 0 to 8 scale, 5 being the cut-off point for a certain diagnose of NASH
and 3–4 being labeled as borderline steatohepatitis [36, 37].
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Currently, even though liver biopsy is still regarded as the “gold standard” when diagnos‐
ing these conditions, no consensus has been reached. Liver biopsy remains therefore a con‐
troversial decision which ultimately has to be performed only when a clear diagnosis cannot
be extracted from serum values, imagistic findings and clinical features [38].
5.3. Metabolic liver disease
Diseases that determine intrahepatic iron accumulation are the main indications for liver bi‐
opsy when a metabolic condition is suspected, besides NAFLD or ALD. Hereditary hemo‐
chromatosis, in its various forms identified today, is routinely diagnosed and staged
through liver biopsy [8, 39]. The metabolic syndrome (syndrome X) represents the increased
accumulation of iron within hepatocytes, in the context of NAFLD. These deposits are not
distributed equally among various regions of the liver, therefore deeper biopsies are needed
in order to collect more tissue for analysis [8, 40]. For this purpose, at least two scores are
currently used – the Deugnier and the Brissot scores [41, 42]. The hepatic iron index is calcu‐
lated through a mathematical formula which takes into account the hepatic iron concentra‐
tion (evaluated by liver biopsy), its atomic weight as well as the age of the patients. An
index above 1.9 is an indicator of hemochromatosis; however its sensitivity is low as it is de‐
pendent on the timing of the liver biopsy [8].
5.4. Focal liver lesions
Discovery of a focal liver lesions (FLL) can occur after imaging tests used routinely for either
screening or diagnosis. The practitioner may encounter lesions of various sizes, number and
location, some of them being associated with pre-existing conditions. This is especially the
case of primary liver malignant tumors, either hepatocellular carcinoma (HCC) or cholan‐
gyocarcinoma (CC). Early discovery of a FLL is possible in up to 60% of all cases, especially
in developed countries where surveillance programs are well established and health serv‐
ices are available to the majority of the population, irrespective of their location and eco‐
nomic status [43, 44].
Imaging alone is currently the main diagnostic procedure for HCC, as modern contrast-en‐
hanced techniques, either by CT or MRI, are sufficient to highlight the hallmark pattern of
tumor vascularization. Diagnostic criteria in the United States of America, Europe and Asia
stipulate that imaging techniques are sufficient to diagnose the majority of HCC lesions, bi‐
opsy being reserved for the few situations where imaging is unclear, discordance between
two methods exists, or tumor size does not allow a precise imaging diagnosis [43–45]. A de‐
fining criteria for evaluating FLLs is the presence of an underlying hepatic condition such as
hepatitis or cirrhosis.
When HCC is suspected in cirrhotic patients, criteria for liver biopsy are set by the size of
the tumor. In nodules between 1 and 2 centimeters, diagnosis should ideally be based on
non-invasive criteria; however, confirmation through biopsy should be sought whenever
possible. The evaluation should be performed ideally by a pathologist with extensive experi‐
ence in evaluating liver biopsies. In case of inconclusive findings after the initial biopsy, a
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second one should be performed if no other imaging criteria are present during the evalua‐
tion period. Nodules larger than 2 centimeters discovered through routine US should be ide‐
ally diagnosed through non-invasive procedures; however, when radiological findings are
atypical, a liver biopsy should be obtained as confirmation [43–45]. A panel of immunohisto‐
chemical markers was proposed as diagnostic when evaluating liver biopsies for HCC. A
combination of glypican 3, heat shock protein 70 and glutamine synthetase are recommend‐
ed for the differential diagnosis between early HCC and high grade dysplastic nodules [46]
(Di Tomaso et al, 2009). A final recommendation of the EASL-EORTC guidelines is that liver
biopsy should be performed within controlled settings of scientific research, for identifying
new markers for HCC and for tissue bio-banking[44].
The current tendency in diagnostic medicine is to avoid liver biopsy when evaluating HCC
[44]. The main reasons against performing liver biopsy are the high rate of sampling errors
which would diminish the sensitivity of the investigation; a higher rate of recurrence post-
transplant in patients who underwent liver biopsy and finally the small but well-established
risk of needle track seeding. In transplant referral centers, liver biopsy is performed more
frequently, as there is an increased need for a correct final diagnosis; however, these proce‐
dures are subject to wide variation depending on country-specific regulations [43, 44]. An‐
other argument for liver biopsy in HCC cases that benefit from chemotherapy would be the
importance of histological grading. Response to local or systemic anti-angiogenic or anti-
proliferative agents might be dictated by the microscopic configuration of the tumor and the
amount of angiogenesis markers present on histological samples [16].
The second most important primary liver malignancy is CC. It can also develop in the pres‐
ence of an underlying liver condition, such as chronic biliary tract diseases. Imaging diagno‐
sis is sometimes difficult, as it may present similar contrast-enhancing patterns to those of
HCC – the majority of CCs are solitary masses present in the hilum, while a minority can
develop in other regions [43, 44]. Mixed forms of CC/HCC may also be present, their non-
invasive diagnosis being even more difficult. All these forms of either atypical CCs or mixed
presentations are usually subjected (with various degrees of variability, depending on set‐
ting and context) to liver biopsy. Surgical intervention, either by resection or liver trans‐
plant, are the approaches that yield the best survival chances for the patient. Therefore, liver
biopsy may be indicated, as well as concomitant biopsy of lymph nodes in the upper ab‐
dominal area [16].
Metastases have the overall highest incidence amongst malignant liver lesions [47]. When a
secondary malignant liver lesion is suspected and the physician cannot identify the primary
point, liver biopsy is usually diagnostic, even when imaging fails to provide enough detail.
If an underlying parenchymal disease is also suspected, biopsy should be performed outside
the lesion site as well, for an extended and more precise diagnosis. A vast panel of markers
may be employed in an immunohistochemistry study; however, the histologic architecture
identified through normal techniques may be sufficient for an expert pathologist to deter‐
mine the primary site of origin [1, 16].
Other rare primary liver parenchyma or bile duct malignant or benign neoplasms can ulti‐
mately be identified through histological analysis, after careful imaging-guided liver biop‐
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sy is performed. This diagnosis is often not possible on cross-sectional imaging studies as
well as tumor serum markers, as their specificity for such lesions is inadequate. An expert
hepatologist should closely collaborate with an experimented pathologist, as the diagnosis
is difficult most of the times. These lesions may develop in the presence of an underlying
liver  condition,  which  would  aid  the  clinical  diagnosis  or  suspicion  on  the  part  of  the
clinician [1, 16].
The majority of lesions discovered through imaging techniques in patients without pre-ex‐
isting liver conditions are benign in origin, mostly solitary or occasionally multiple. They ex‐
hibit particular vascular patterns in contrast-enhanced imaging techniques and are thus
easily diagnosed without the use of invasive techniques. Such is the case of liver hemangio‐
mas, mostly solitary benign tumors with characteristic contrast enhancement throughout all
phases of an imaging investigation. Other lesions such as focal nodular hyperplasia are also
usually solitary and may display distinct features such as “central scarring” or particular en‐
hancement patterns (spiked wheel enhancement etc.). All these particularities have a mor‐
phological substrate: central hypoechoic areas which do not show vascular
hyperenhancement usually correspond to areas of necrosis; intense signal enhancement
zones are indicators of high microvessel density and neo-angiogenesis vessels; the US or CT
peripheral rim translate in certain particularities of fibrous capsules [1, 16, 44].
Overall, lesions may present as cystic, solid or vascular; all these particularities usually be‐
ing identified through non-invasive procedures prior to liver biopsy. In the USA for in‐
stance, liver biopsy is performed by imagists as they can perform the pre-biopsy or real-time
assessment of the procedure, while in Europe most gastroenterologists or hepatologists per‐
form the procedure themselves, under US surveillance [43, 44]. A core biopsy is usually pre‐
ferred to fine-needle aspiration, as histology is considered superior from a diagnostic
perspective compared to cytology; another reason being that experts in evaluating histology
are more numerous compared to cytologists. The risk of puncturing blood vessels, either
major arteries in the normal parenchyma, or intra-tumoral vessels is considerably diminish‐
ed by real-time imaging guidance, for instance US with color Doppler. The risk of track
seeding exists, even if extremely low (one study estimates a risk of 0.13%, while in other
studies no such incidents were reported) [48, 49]. A certain dependency on the technique
and size of the needle was also proven [50]. Infectious lesions may be biopsied; even if echi‐
nococcal cysts were considered an absolute contraindication as puncturing can be associated
with anaphylactic shock and death, it was proven that these lesions can be aspirated with 19
or 22-gauge needles, taking all preparations for possible anaphylaxis [51].
6. Novel techniques in liver biopsy; modern non-invasive alternatives
6.1. Probe-based confocal laser endomicroscopy
The latest development in histological evaluation of gastrointestinal structures is confocal la‐
ser endomicroscopy. It allows for the in vivo evaluation of dysplasia and malignancies of
the gastrointestinal tract, or in order to obtain directed biopsies that would allow rapid and
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more precise diagnoses [52, 53]. The first embodiments of this technique required dedicated
endoscopes to be used for evaluating cavitary structures accessible from both ends of the di‐
gestive tracts.
Recent advancements however were able to miniaturize the technology so the imaging mi‐
croprobe can be connected to 30,000 fiber-optic threads that enable point-to-point real-time
detection at 12 frames/sec. The imaging device by itself measures less than 1.5 millimeters in
diameter, thus allowing its use through 19G or tru-cut biopsy needles, or insertion by lapa‐
roscopy or NOTES [53]. This technology will allow in vivo, real-time imaging of liver histol‐
ogy, technically enhancing the capabilities of liver biopsy [54]. A few studies on animal
models exist in the literature, detailing pCLE use for liver histological imaging [14, 55, 56].
The technique can be used for assessing the state of hepatocytes and the morphology of the
liver tissue, or can be limited to the study of the exterior liver capsule, yielding interesting
preliminary results in the setting of cirrhosis. Mennone et al reported interesting results re‐
garding a fibrotic pattern and collagen deposits in animal models with cirrhosis induced by
bile duct ligation [14]. The technology shows promise and may someday allow for safer his‐
tological assessment of patients with chronic liver disease irrespective of its advancement,
either cirrhotic or having any extreme complications, such as HCC.
6.2. Non-invasive imaging and serum tests for the assessment of fibrosis
Transient elastography (TE, Fibroscan® developed by Echosens, Paris, France) and Acoustic
radiation force impulse (ARFI) are two ultrasound-based methods for quantifying liver fib‐
rosis without the need for histological assessment. Another approach is through serum
markers of fibrosis quantification, processed in complex mathematical formulas which give
a quantitative result for liver stiffness, such as the Fibrotest, Biopredictive and the aspartate
transaminase to platelets ratio index (ARPI) approaches.
TE is a novel and rapid non-invasive examination which involves minimal patient discom‐
fort over a relatively low time period (one examination may take up to 5-10 minutes de‐
pending on the skeletal and adipose conformations of the patient). The device consists of a
hand-held vibrating unit with an ultrasound transducer probe mounted on its axis, which
generates medium amplitude vibrations at a low frequency, thus inducing an elastic shear
wave in the underlying tissue. The hand-held probe is connected to a modified tower US
machine which registers the result and through the on-screen software interface presents the
user with an elastogram as a function of depth in time. The patient lies on his/her side and
the probe is placed against the skin on the median clavicle line, directed towards the ana‐
tomical location of the liver, at a 90 degrees angle with the skin surface. Its results are pre‐
sented as kilo Pascals (kPa), units of applied force. A series of 10 measurements are
mediated to present a final value of the liver stiffness, which is equivalent to an F-stage fib‐
rosis measurement obtained through biopsy [2].
ARFI is another technology that uses short-duration, high-intensity acoustic pulses which in
turn exert mechanical excitation upon the tissues, generating local displacement resulting in
shear waves. Their velocity can be assessed in a selected cylindrical area of interest of 0.5 cm
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(length) x 0.4 cm (diameter), up to 5.5 cm below skin level. Its results are expressed as veloci‐
ties, in m/s [4].
Fibrotest-Actitest (Biopredictive, France) is a serologic marker-based algorithm which repre‐
sents an alternative to invasive biopsy techniques. It received clinical validation in patients
with chronic hepatitis B and C, ALD and NAFLD. Fibrotest consists of a panel of markers
designed for appreciating liver fibrosis: Gamma-glutamyltranspeptidase (GGT), Total biliru‐
bin Alpha-2-macroglobulin, Haptoglobin, and Apolipoprotein A1. Necroinflammatory ac‐
tivity is appreciated through the Actitest component, which adds Alanine transaminase
(ALT) to the above mentioned serum markers [3, 57]. All these tests are performed in vali‐
dated laboratories due to their complexity and variability of their different components and
their results are inserted in a complex mathematical formula through a web-based interface,
the end-result being correlated with other quantitative score systems such as METAVIR,
Knodell or Ishak [58].
The best results are provided by a combination of two or more non-invasive methods, one
study in particular finding that Fibrotest and Fibroscan offers the best diagnosis perform‐
ance compared to liber biopsy as a gold standard, at least for advanced fibrosis (F values
beyond 2) or cirrhosis (F3 or F4) [2]. This conclusion was reached by another, more recent
study performed by Boursier and his collaborators [59]. They diminish the number of pa‐
tients who require liver biopsy, however, this procedure is not excluded in all cases. Some
studies have shown a high variability between Fibroscan results, dependent of the body-
mass index and population factors [60, 61]. A discordance between liver biopsy staging and
the estimation provided by non-invasive methods has also been identified [34]. It was ap‐
proximated that 30–40% of all patients investigated by a combination of non-invasive imag‐
istic and marker-based methods still require liver biopsy, during either sequential or
simultaneous protocols [60, 61].
7. Conclusion
Despite all its limitations and the advances in modern lesser invasive techniques, liver biop‐
sy remains the gold standard for evaluating a wide array of liver diseases.
The main concern when turning to tissue sampling through biopsy is the risk/benefit ra‐
tio, the decision ultimately belonging to the clinician involved. The risks may at times be
higher than the implied diagnostic  outcome,  in which case other methods are preferred
for the diagnosis.
Currently, it is recommended that all interpretations should be based on proper tissue
blocks, with the correct technique applied. It is preferred that more than one pathologist
with extensive experience in liver pathology should formulate the final histological diagno‐
sis. This is especially true for FLLs and liver malignancies, as benign features may at times
overlap, making the diagnosis uncertain.
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Modern imagistic techniques allow for precise non-invasive evaluation of liver fibrosis in
the context of hepatitis; however, the correct methodology for interpreting these tests is yet
to be established. Novel imagistic approaches may in time open new perspectives for liver
biopsy, by providing in vivo, real time data on liver parenchymal features which would
prove useful for accurate diagnosing of otherwise difficult to interpret pathologies.
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